» Articles » PMID: 2746493

Kinetic and Dynamic Study of Intravenous Lorazepam: Comparison with Intravenous Diazepam

Overview
Specialty Pharmacology
Date 1989 Jul 1
PMID 2746493
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Six healthy volunteers received a single i.v. dose of 'low dose' lorazepam (0.0225 mg/kg), 'high dose' lorazepam (0.045 mg/kg) and placebo by 1-min infusion in a double-blind three-way crossover study. Plasma concentrations were measured 24 hr after dosage, and the EEG power spectrum was simultaneously computed by fast-Fourier transform to determine the percentage of total EEG amplitude occurring in the 13-30-Hz range. Low and high dose lorazepam did not differ significantly in distribution volume (1.89 versus 1.81 l/kg) or elimination half-life (11.5 versus 12.2 hr); clearance was slightly although significantly reduced at the higher dose (2.08 versus 1.88 ml/min/kg, P less than .005). EEG effects were of relatively slow onset, reaching their maximum change over baseline 30 min after infusion. The duration of action was prolonged, with the fraction of EEG activity in the 13-30-Hz range still significantly above baseline 8 hr after the 0.045 mg/kg dose. Five of these subjects received 0.15 mg/kg of i.v. diazepam in a companion study of identical design. EEG effects of diazepam were shorter than those of lorazepam, probably because of the more rapid and extensive decline in plasma diazepam concentrations in the postinfusion distribution phase. In addition, the onset of diazepam's effect was immediate. In male CD-1 mice that received i.v. diazepam (8.3 mg/kg) or lorazepam (3.3 mg/kg), the brain:plasma concentration ratio was maximal 2.5 min after dosage for diazepam, but equilibration was delayed at least 30 min after dosage for lorazepam. Thus the slow onset of action of lorazepam is probably attributable to slow entry into brain.

Citing Articles

Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.

Kienitz R, Kay L, Beuchat I, Gelhard S, von Brauchitsch S, Mann C CNS Drugs. 2022; 36(9):951-975.

PMID: 35971024 PMC: 9477921. DOI: 10.1007/s40263-022-00940-2.


Antiepileptic Drug Therapy for Status Epilepticus.

Kim D, Kim J, Cho Y, Yang K, Kim D, Lee S J Clin Neurol. 2021; 17(1):11-19.

PMID: 33480193 PMC: 7840311. DOI: 10.3988/jcn.2021.17.1.11.


Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.

Hui D, Frisbee-Hume S, Wilson A, Dibaj S, Nguyen T, De La Cruz M JAMA. 2017; 318(11):1047-1056.

PMID: 28975307 PMC: 5661867. DOI: 10.1001/jama.2017.11468.


Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal.

Weintraub S CNS Drugs. 2017; 31(2):87-95.

PMID: 28101764 DOI: 10.1007/s40263-016-0403-y.


Pain management in neurocritical care.

Petzold A, Girbes A Neurocrit Care. 2013; 19(2):232-56.

PMID: 23893074 DOI: 10.1007/s12028-013-9851-0.